Current treatment status-Did not start treatment yet - Page 11 of 37 Posts on Medivizor

Looking for patients with breast cancer who will be undergoing mastectomy to examine the incidence of chronic pain when Pulsed Electromagnetic Fields (PEMF) and Pectoral (PEC) Interfascial Blocks are used.

Posted by Medivizor on Feb 3, 2018 in Breast cancer | 0 comments

In a nutshell This trial is examining the effectiveness of pulsed electromagnetic field (PEMF) or an anesthetic bupivacaine in lowering the incidence of chronic pain after surgery. The main outcome to be measured will be the incidence of chronic pain after each treatment. This study is being conducted in New York City. The...

How safe and effective is R-CHOP as a first-line treatment for patients with FL in the long-term?

Posted by Medivizor on Jan 27, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of R-CHOP (rituximab combined with cyclophosphamide, doxorubicin, vincristine, prednisone) to CHOP-RIT (CHOP followed by iodine-133-tositumomab, Bexxar) as a first-line treatment for follicular lymphoma (FL) patients. This study concluded that immunochemotherapy should remain the standard...

Weekly carfilzomib, cyclophosphamide, and dexamethasone in multiple myeloma

Posted by Medivizor on Jan 26, 2018 in Multiple Myeloma | 0 comments

In a nutshell This paper studied the outcome of weekly carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma who cannot be treated with transplant. The authors concluded that this combination was effective in these patients. Some background Multiple myeloma is a cancer of the plasma cells of the blood....

Combining systemic and local therapy – is there a benefit for patients with advanced non-small-cell lung cancer?

Posted by Medivizor on Jan 17, 2018 in Lung cancer | 0 comments

In a nutshell This study looked at different combinations of local and systemic therapy for treating patients with advanced non-small-cell lung cancer (NSCLC). The authors concluded that this type of aggressive combination therapy could improve survival rates of these patients. Some background Roughly half of patients with NSCLC are not diagnosed...

Oxaliplatin in the treatment of colorectal cancer in elderly patients

Posted by Medivizor on Jan 15, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the safety of oxaliplatin to treat colorectal cancer in elderly patients. Researchers suggested that oxaliplatin treatment is associated with neuropathy (numbness of arms or legs) in these patients. Some background Colorectal cancer is one of the most common forms of cancer among the elderly....

Side effects of treatment in multiple myeloma

Posted by Medivizor on Jan 12, 2018 in Multiple Myeloma | 0 comments

In a nutshell This paper reviewed the side effects of drugs used in the treatment of multiple myeloma. Some background Treatment for multiple myeloma includes different groups of medications. Immunomodulatory drugs work by changing the function of the immune systems. Proteasome inhibitors work by blocking the breakdown of proteins that are...

Daratumumab plus bortezomib, melphalan, and prednisone for newly diagnosed myeloma

Posted by Medivizor on Dec 30, 2017 in Multiple Myeloma | 0 comments

In a nutshell This paper studied the effect of daratumumab together with bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma. The study found that the addition of daratumumab improved survival. Some background Multiple myeloma is a cancer of the plasma cells of the blood. Daratumumab (Darzalex) is a drug...

First-line tyrosine kinase inhibitors: Comparing bosutinib and imatinib

Posted by Medivizor on Dec 30, 2017 in Leukemia | 0 comments

In a nutshell This study compared the effectiveness of two types of tyrosine kinase inhibitors – imatinib (Gleevac) and bosutinib (Bosulif) – for chronic myeloid leukemia (CML). Researchers reported higher treatment response rates with bosutinib than with imatinib. Some background Many patients with CML...

Early outcomes of proton therapy after chemotherapy

Posted by Medivizor on Dec 20, 2017 in Hodgkin's lymphoma | 0 comments

In a nutshell This study examined outcomes for patients with Hodgkin lymphoma receiving chemotherapy followed by proton therapy. Researchers reported good disease control and a low rate of side effects at 3 years. However, continued follow-up is needed. Some background The combination of chemotherapy and radiation therapy provides the best...

Comparing transplant options for patients with acute myeloid leukemia and acute lymphoblastic leukemia

Posted by Medivizor on Dec 9, 2017 in Leukemia | 0 comments

In a nutshell This study aimed to compare unrelated donor umbilical cord blood transplant and unrelated hematopoietic stem cell transplant in adult and pediatric patients with acute myeloid leukemia and acute lymphoblastic leukemia. This study concluded that unrelated donor umbilical cord blood transplants could be used more often as a treatment...

Impact of delayed sentinel lymph node biopsy in early melanomas

Posted by Medivizor on Dec 7, 2017 in Melanoma | 0 comments

In a nutshell This study investigated the impact of the time between diagnosis and sentinel lymph node biopsy (SLNB) in melanoma outcomes. Researchers suggested that no negative effects are associated with delayed SLNB. Some background SLNB is a procedure used to detect lymph node metastasis (spread disease) in melanoma patients. The...

Partial gland ablation versus prostate surgery in men with low- or intermediate-risk prostate cancer

Posted by Medivizor on Nov 20, 2017 in Prostate cancer | 0 comments

In a nutshell The authors aimed to determine patient outcomes following partial gland ablation compared to robot-assisted radical prostate surgery in men with low- and intermediate- risk prostate cancer. The authors concluded that men with cancer confined to the prostate benefited from partial gland ablation, as it was more successful with fewer side...

Current treatment status-Did not start treatment yet Posts on Medivizor

Looking for patients with breast cancer who will be undergoing mastectomy to examine the incidence of chronic pain when Pulsed Electromagnetic Fields (PEMF) and Pectoral (PEC) Interfascial Blocks are used.

How safe and effective is R-CHOP as a first-line treatment for patients with FL in the long-term?

Weekly carfilzomib, cyclophosphamide, and dexamethasone in multiple myeloma

Combining systemic and local therapy – is there a benefit for patients with advanced non-small-cell lung cancer?

Oxaliplatin in the treatment of colorectal cancer in elderly patients

Side effects of treatment in multiple myeloma

Daratumumab plus bortezomib, melphalan, and prednisone for newly diagnosed myeloma

First-line tyrosine kinase inhibitors: Comparing bosutinib and imatinib

Early outcomes of proton therapy after chemotherapy

Comparing transplant options for patients with acute myeloid leukemia and acute lymphoblastic leukemia

Impact of delayed sentinel lymph node biopsy in early melanomas

Partial gland ablation versus prostate surgery in men with low- or intermediate-risk prostate cancer

Categories

Recent Posts

Archives

Current treatment status-Did not start treatment yet Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email